Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection

Vaccine

Volumn 30, Issue 39, 2012, Pages 5726-5732

  Hugentobler, Felix ^a   Di Roberto, Raphaël B ^a   Gillard, Joshua ^a   Cousineau, Benoit ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Department of Microbiology and Immunology   (Canada)

Author keywords

Adjuvant; IL 12; Lactococcus lactis; Leishmaniasis; Live vaccine; Oral immunization

Indexed keywords

INTERLEUKIN 12; LACTOCOCCUS LACTIS VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOPLASM; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LACTOCOCCUS LACTIS; LEISHMANIA MAJOR; LEISHMANIASIS; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; IMMUNITY, MUCOSAL; INTERLEUKIN-12; LACTOCOCCUS LACTIS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPH NODES; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SPLEEN; TH2 CELLS;

EID: 84864958496     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.004     Document Type: Article

References (31)

1. Ameen M. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Clin Exp Dermatol 2010, 35(October (7)):699-705.
2. Ait-Oudhia K., Gazanion E., Vergnes B., Oury B., Sereno D. Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res 2011, 109(November (5)):1225-1232.
3. Mougneau E., Bihl F., Glaichenhaus N. Cell biology and immunology of Leishmania. Immunol Rev 2011, 240(March (1)):286-296.
4. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002, 2(November (11)):845-858.
5. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., et al. Expression cloning of a protective Leishmania antigen. Science 1995, 268(April (5210)):563-566.
6. Gonzalo R.M., Rodriguez J.R., Rodriguez D., Gonzalez-Aseguinolaza G., Larraga V., Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect 2001, 3(July (9)):701-711.
7. Tapia E., Perez-Jimenez E., Lopez-Fuertes L., Gonzalo R., Gherardi M.M., Esteban M. The combination of DNA vectors expressing IL-12+IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003, 5(February (2)):73-84.
8. Pinto E.F., Pinheiro R.O., Rayol A., Larraga V., Rossi-Bergmann B. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Infect Immun 2004, 72(August (8)):4521-4527.
9. Soussi N., Milon G., Colle J.H., Mougneau E., Glaichenhaus N., Goossens P.L. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect Immun 2000, 68(March (3)):1498-1506.
10. Lange U.G., Mastroeni P., Blackwell J.M., Stober C.B. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 2004, 72(August (8)):4924-4928.
11. Hugentobler F., Yam K.K., Gillard J., Mahbuba R., Olivier M., Cousineau B. Immunization against Leishmania major infection using LACK- and IL-12 expressing Lactococcus lactis induces delay in footpad swelling. PLoS ONE 2012, 7(2):e30945.
12. Casalta E., Montel M.C. Safety assessment of dairy microorganisms: the Lactococcus genus. Int J Food Microbiol 2008, 126(September (3)):271-273.
13. Bahey-El-Din M., Gahan C.G., Griffin B.T. Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr Gene Ther 2010, 10(February (1)):34-45.
14. Grangette C., Muller-Alouf H., Hols P., Goudercourt D., Delcour J., Turneer M., et al. Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria. Infect Immun 2004, 72(May (5)):2731-2737.
15. Yam K.K., Hugentobler F., Pouliot P., Stern A.M., Lalande J.D., Matlashewski G., et al. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. J Med Microbiol 2011, 60(September (Pt 9)):1248-1260.
16. Sriraman K., Jayaraman G. HtrA is essential for efficient secretion of recombinant proteins by Lactococcus lactis. Appl Environ Microbiol 2008, 74(December (23)):7442-7446.
17. Kobets T., Badalova J., Grekov I., Havelkova H., Svobodova M., Lipoldova M. Leishmania parasite detection and quantification using PCR-ELISA. Nat Protoc 2010, 5(6):1074-1080.
18. Steen A., Palumbo E., Deghorain M., Cocconcelli P.S., Delcour J., Kuipers O.P., et al. Autolysis of Lactococcus lactis is increased upon D-alanine depletion of peptidoglycan and lipoteichoic acids. J Bacteriol 2005, 187(January (1)):114-124.
19. Stober C.B., Lange U.G., Roberts M.T., Alcami A., Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 2005, 175(August (4)):2517-2524.
20. Yang D.M., Fairweather N., Button L.L., McMaster W.R., Kahl L.P., Liew F.Y. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990, 145(October (7)):2281-2285.
21. Soussi N., Saklani-Jusforgues H., Colle J.H., Milon G., Glaichenhaus N., Goossens P.L. Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection. Vaccine 2002, 20(June (21-22)):2702-2712.
22. Medina E., Guzman C.A. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001, 19(February (13-14)):1573-1580.
23. Tarahomjoo S. Development of vaccine delivery vehicles based on lactic acid bacteria. Mol Biotechnol 2012, 51(June (2)):183-199.
24. Braat H., Rottiers P., Hommes D.W., Huyghebaert N., Remaut E., Remon J.P., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006, 4(June (6)):754-759.
25. Huber V.C., Arulanandam B.P., Arnaboldi P.M., Elmore M.K., Sheehan C.E., Kallakury B.V., et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 2003, 3(June (6)):801-809.
26. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90(October (7)):2541-2548.
27. Kedzierski L. Leishmaniasis vaccine where are we today?. J Glob Infect Dis 2010, 2(May (2)):177-185.
28. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6(May (5)):349-362.
29. Robinson K., Chamberlain L.M., Lopez M.C., Rush C.M., Marcotte H., Le Page R.W., et al. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infection & Immunity 2004, 72(5):2753-2761.
30. Miles S.A., Conrad S.M., Alves R.G., Jeronimo S.M., Mosser D.M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005, 201(March (5)):747-754.
31. Noben-Trauth N., Lira R., Nagase H., Paul W.E., Sacks D.L. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 2003, 170(May (10)):5152-5158.